The panic disorder market is gaining increasing attention due to the growing emphasis on mental health and the rising prevalence of anxiety disorders worldwide. With a market size valued at USD 9.7 billion in 2024 across the 7 major markets (7MM), the industry is witnessing sustained momentum. It is projected to grow at a CAGR of 4.18% between 2025 and 2034, reaching a total value of USD 14 billion by 2034.
This article presents a detailed analysis of the panic disorder market, including its size and share, dynamics, emerging trends, opportunities, key players, recent developments, and frequently asked questions.
Overview of the Panic Disorder Market
Panic disorder is a type of anxiety disorder marked by recurrent, unexpected panic attacks—sudden periods of intense fear or discomfort accompanied by physical and cognitive symptoms. These include palpitations, sweating, chest pain, nausea, and fear of losing control.
As awareness around mental health continues to grow, more individuals are seeking diagnosis and treatment, leading to a surge in demand for pharmaceutical interventions, therapy, and digital solutions. The panic disorder market spans medications (SSRIs, SNRIs, benzodiazepines), behavioral therapies, and mobile mental health applications.
Panic Disorder Market Size and Share Analysis
In 2024, the panic disorder market size across the 7 major markets (United States, Germany, France, Italy, Spain, United Kingdom, and Japan) was valued at USD 9.7 billion. The market is poised to reach USD 10.1 billion in 2025 and further expand to USD 14 billion by 2034.
This steady growth reflects the increasing burden of anxiety disorders and the societal shift towards mental well-being. The United States holds the largest share, followed by European nations and Japan, owing to better healthcare access, mental health programs, and reimbursement policies.
Market Dynamics and Emerging Trends
Rising Mental Health Awareness
Global campaigns and national efforts have significantly improved public understanding of mental health conditions like panic disorder. Governments and NGOs are investing in mental health education and services, improving diagnosis and treatment rates.
Technological Advancements
Telepsychiatry and digital health platforms are transforming how panic disorder is diagnosed and treated. Mobile applications and AI-powered platforms now aid in early diagnosis and offer cognitive behavioral therapy (CBT) remotely, increasing access in underserved regions.
Shift Toward Personalized Medicine
Pharmaceutical companies are focusing on tailoring treatments based on genetic and biological markers. Personalized treatments improve efficacy and reduce side effects, making them highly appealing to both clinicians and patients.
Integration of Behavioral Therapies
In addition to pharmacological treatments, therapy-based interventions—especially CBT and exposure therapy—are gaining traction. This integrated approach has been shown to yield better outcomes, encouraging healthcare providers to adopt a more holistic model.
Explore the Future of Dialysis Services in the U.S.! Gain exclusive insights into market trends, opportunities, and challenges. Download Your FREE Report Today! Access Now.
Key Growth Drivers of the Panic Disorder Market
Increased Diagnosis and Screening: More individuals are undergoing mental health assessments, leading to early detection of panic disorder.
Changing Lifestyles and Stress Levels: Urbanization, social isolation, and workplace stress are contributing to higher anxiety levels globally.
Supportive Healthcare Policies: Mental health is becoming a budgetary priority for many governments, with insurance coverage improving in several regions.
Innovative Drug Development: New classes of anxiolytics with fewer side effects are under development, expanding treatment options.
Market Opportunities and Challenges
Opportunities
Emergence of Digital Therapeutics: Smartphone-based therapies and wearable mental health monitors present untapped potential.
Rising Demand in Emerging Economies: Countries like India, Brazil, and China are seeing growing awareness and treatment-seeking behavior.
Collaborative Research Initiatives: Partnerships between pharma companies and academic institutions are accelerating drug discovery.
Challenges
Stigma Around Mental Health: In many regions, stigma continues to delay treatment.
High Relapse Rates: Current treatments often manage symptoms rather than provide a long-term cure, necessitating better solutions.
Side Effects of Medications: SSRIs and benzodiazepines, the most common treatments, are associated with adverse effects and dependency risks.
Recent Developments in the Panic Disorder Market
Neurocrine Biosciences, Inc. is advancing novel treatments targeting the central nervous system, with promising outcomes in anxiety disorders.
GlaxoSmithKline plc has strengthened its psychiatric pipeline with molecules designed for improved receptor targeting.
Eli Lilly and Company continues to explore new SSRI formulations with better tolerability and longer action.
Recordati S.p.A. is expanding its therapeutic portfolio for psychiatric conditions through collaborations in Europe and the U.S.
Digital health integration is another major area of innovation. Companies are investing in AI-powered chatbots, mental wellness platforms, and app-based therapy programs that support traditional medication.
Panic Disorder Market Growth Forecast
The panic disorder market is expected to grow steadily, increasing from USD 10.1 billion in 2025 to USD 14 billion in 2034, at a CAGR of 4.18%. This growth is underpinned by several factors:
Increased mental health investments globally.
Continuous drug development and approval of new molecules.
Expanding patient base due to heightened stress-related conditions post-COVID-19.
Strong commercial interest in CNS-focused therapeutics.
Competitive Landscape and Key Player Analysis
The panic disorder market is highly competitive, comprising global pharmaceutical giants and specialized mental health companies. The focus is on enhancing efficacy, reducing side effects, and integrating digital therapeutics.
Key Players in the Panic Disorder Market
Teva Pharmaceutical Industries Ltd: Offers a wide range of generics and branded treatments for psychiatric disorders.
Sun Pharmaceutical Industries Ltd.: Active in developing affordable therapies for anxiety and mood disorders, especially in emerging markets.
Mylan: Focuses on expanding access to generic medications used in panic and anxiety disorders.
AstraZeneca: Engaged in neuroscience R&D to develop novel anxiolytics and mood stabilizers.
Abbott: Provides solutions across pharmaceutical and diagnostic segments for anxiety-related disorders.
Baxter: Offers supportive care products and is investing in behavioral health tech partnerships.
Bristol-Myers Squibb Company: Involved in CNS drug research and strategic partnerships for mental health.
Eli Lilly and Company: Known for its strong psychiatric pipeline, including SSRIs and emerging therapies for generalized anxiety and panic.
F. Hoffmann-La Roche Ltd: Leveraging biologics and targeted therapy for neurological and psychiatric care.
GlaxoSmithKline plc: Maintains a significant presence in the mental health space with legacy products and ongoing R&D.
Recordati S.p.A.: Focused on CNS conditions with recent licensing agreements for anti-anxiety medications.
Boehringer Ingelheim International GmbH: Investing in novel targets for anxiety and depressive disorders.
Neurocrine Biosciences, Inc.: Specializes in neurological and psychiatric disorders with ongoing clinical trials for next-generation treatments.
These companies are using clinical research, mergers, digital expansion, and regional market penetration strategies to maintain a competitive edge.
Frequently Asked Questions (FAQ)
What is panic disorder?
Panic disorder is a type of anxiety disorder characterized by sudden, repeated episodes of intense fear or discomfort, known as panic attacks.
What are the common treatments for panic disorder?
Treatment typically includes medication such as SSRIs, SNRIs, benzodiazepines, and psychotherapy like cognitive behavioral therapy (CBT).
What is the size of the panic disorder market?
The market was valued at USD 9.7 billion in 2024 and is expected to reach USD 14 billion by 2034, growing at a CAGR of 4.18%.
Which regions lead the panic disorder market?
The United States is the dominant region, followed by Europe and Japan. Growing awareness in emerging markets is also contributing to expansion.
Who are the major players in this market?
Key players include Teva, Sun Pharma, Mylan, AstraZeneca, Abbott, Eli Lilly, Roche, GSK, Recordati, and Neurocrine Biosciences, among others.
What are the main factors driving market growth?
Rising awareness, digital therapeutic advancements, increasing stress levels, and greater access to mental healthcare are driving growth.
What challenges does the market face?
Key challenges include stigma, medication side effects, high relapse rates, and limited access to treatment in developing nations.
Find More Report:
regenerative medicine market size
About Us:
Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others. Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector.
Media Contact:
Company Name: Claight Corporation
Contact Person: Deepanshu Choudhary, Digital Marketing
Email: sales@expertmarketresearch.com
Toll Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com
